GlassScriptPhysician profile
Jessica Chu
NPI 1063076586
$3,665.06
in general payments reported to CMS, 2019-2025
29 companies · $1,232 in 2025
The $1,232 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $127 · 2023: $257 · 2024: $2,049 · 2025: $1,232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,537.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $641.62 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $471.40 | 2024-2025 | Evenity, Tepezza, Prolia |
| Dexcom, INC. | $404.71 | 2024-2025 | Dexcom G6 Transmitter |
| Beta Bionics, INC. | $392.91 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Lilly USA, LLC | $285.90 | 2023-2025 | Mounjaro, Zepbound |
| Xeris Pharmaceuticals, INC. | $242.09 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Sanofi-Aventis U.S. LLC | $150.77 | 2024-2025 | |
| Corcept Therapeutics | $114.24 | 2023-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $108.53 | 2022 | |
| Merck Sharp & Dohme LLC | $94.63 | 2024 | Dificid, Delstrigo, Pifeltro |
| Alexion Pharmaceuticals, INC. | $92.97 | 2024-2025 | Strensiq |
| Ascensia Diabetes Care US INC. | $66.93 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.29 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $61.04 | 2023-2024 | Unithroid |
| Medtronic, INC. | $59.73 | 2023-2025 | Minimed 780g |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $59.24 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Pfizer INC. | $55.32 | 2023-2025 | |
| Antares Pharma, INC. | $55.20 | 2024-2025 | Xyosted |
| Radius Health, INC. | $49.54 | 2024 | Tymlos |
| Ibsa Pharma INC. | $26.93 | 2023-2024 | Flector, Licart, Tirosint |
| Theratechnologies INC. | $23.33 | 2024 | Egrifta, Trogarzo |
| Recordati_rare_diseases_inc. | $22.97 | 2025 | Isturisa |
| Insulet Corporation | $21.42 | 2024 | Omnipod |
| Esperion Therapeutics, INC. | $19.30 | 2023 | Nexletol |
| Glaxosmithkline, LLC. | $18.64 | 2022 | |
| Ascendis Pharma Endocrinology INC | $18.63 | 2025 | Yorvipath |
| Sequel Med Tech, LLC | $17.88 | 2025 | Twiist |
| Shield Therapeutics INC | $14.15 | 2023 | Accrufer |
| Cequr Corporation | $11.75 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.